Dermira Inc (NASDAQ:DERM) SVP Christopher M. Griffith sold 18,458 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total transaction of $499,288.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of Dermira Inc (NASDAQ DERM) traded down $0.60 during mid-day trading on Friday, reaching $27.48. 87,679 shares of the company’s stock traded hands, compared to its average volume of 587,760. The company has a debt-to-equity ratio of 1.40, a current ratio of 4.68 and a quick ratio of 4.68. The firm has a market capitalization of $1,170.00, a P/E ratio of -4.41 and a beta of 0.80. Dermira Inc has a 1 year low of $21.35 and a 1 year high of $38.75.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its position in Dermira by 15.6% during the second quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock worth $114,294,000 after acquiring an additional 529,405 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Dermira by 0.3% during the third quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock worth $71,300,000 after purchasing an additional 7,746 shares during the period. Vanguard Group Inc. increased its holdings in shares of Dermira by 9.8% during the second quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock worth $40,735,000 after purchasing an additional 125,157 shares during the period. Voya Investment Management LLC increased its holdings in shares of Dermira by 61.4% during the second quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock worth $35,783,000 after purchasing an additional 467,356 shares during the period. Finally, State Street Corp increased its holdings in shares of Dermira by 38.4% during the second quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock worth $23,946,000 after purchasing an additional 228,093 shares during the period. Hedge funds and other institutional investors own 99.47% of the company’s stock.

DERM has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of Dermira from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Cantor Fitzgerald restated a “buy” rating and set a $45.00 price objective on shares of Dermira in a research note on Tuesday, September 26th. Leerink Swann restated an “outperform” rating and set a $41.00 price objective (down from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Needham & Company LLC restated a “buy” rating and set a $43.00 price objective (down from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Finally, Mizuho restated a “buy” rating and set a $43.00 price objective (up from $40.00) on shares of Dermira in a research note on Thursday, September 7th. Three equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $41.00.

TRADEMARK VIOLATION NOTICE: “Dermira Inc (DERM) SVP Christopher M. Griffith Sells 18,458 Shares of Stock” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/dermira-inc-derm-svp-christopher-m-griffith-sells-18458-shares-of-stock/1795761.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with Analyst Ratings Network's FREE daily email newsletter.